Optic Neuritis Treatment Market Insights, Size, Share Analysis and Research Report 2023-2030

Market Overview 

Global Optic Neuritis Treatment Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a high CAGR during the forecast period 2023-2030. 

Optic neuritis is a condition characterized by inflammation or irritation of the optic nerve, which connects the eye to the brain. It can occur either as a result of an underlying disease or without a specific known cause. Notably, individuals with optic neuritis are at risk of developing multiple sclerosis. 

Common symptoms of optic neuritis include pain when moving the affected eye and temporary vision loss in one eye. 

In some cases, optic neuritis may spontaneously resolve without the need for treatment. However, when visual function is significantly impaired, a treatment regimen involving steroid medication is typically recommended. Intravenous methylprednisolone, followed by a tapering course of oral steroids, is often administered, as it has been shown to expedite the recovery of visual function. This regimen typically involves three days of intravenous steroid treatment, followed by several days of gradually decreasing oral medication. 

In instances where steroid therapy proves ineffective and severe vision loss persists, some individuals may explore plasma exchange therapy as a potential treatment option. However, it's important to note that while this therapy may help certain individuals regain their vision, further research is required to conclusively establish its efficacy in the context of optic neuritis. 

For More Insights Request Free Sample: https://www.datamintelligence.com/download-sample/optic-neuritis-treatment-market 

Market Drivers 

The global market is witnessing an escalating demand for innovative therapeutics, which is poised to be a driving force throughout the forecast period. These novel treatments are designed to address the unmet needs in the realm of optic neuritis, offering alternative or complementary solutions for more effective disease management. 

For example, on July 6, 2023, Horizon Therapeutics shared encouraging data from a late-stage study of Uplizna (inebilizumab-cdon) in patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD), a condition frequently characterized by optic neuritis. 

Furthermore, regulatory approvals, such as those from the FDA, play a pivotal role in instilling trust in patients and showcasing improved outcomes in the treatment of optic neuritis. An illustrative instance is the FDA's approval of Genentech's Enspryng (satralizumab-mwge) on August 14, 2020, marking it as the first and only subcutaneous treatment for adults dealing with anti-aquaporin-4 (AQP4) antibody optic neuritis. This development has significant implications for the field, providing patients with new and promising therapeutic options. 

Request For Customize Report: https://www.datamintelligence.com/customize/optic-neuritis-treatment-market 

Market Segmentation 

By Disease Type 

• Retrobulbar Neuritis 
• Papillitis  
• Perineuritis 
• Neuroretinitis  

By Treatment Type 

• Oral Corticosteroids 
• Intravenous Corticosteroids 
• Others  

By Distribution Channel 

• Hospital Pharmacies 
• Retail Pharmacies 
• Online Pharmacies 

Market Key players 

Major players are Pfizer Inc., MERCK & CO., Inc., EyePoint Pharmaceuticals, Inc., Novartis AG, Genentech, Inc., Mallinckrodt plc, Alcon Inc., NIKSAN PHARMACEUTICAL, AbbVie Inc. and Hubei Gedian Humanwell Pharmaceutical Co., Ltd. 

Trending Reports 

Coloboma Treatment Market 

Persistent Epithelial Defect Treatment Market 

Bullous Keratopathy Treatment Market 

Retinal Neovascularization Market 

Mydriasis Treatment Market

About Us -

DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us -

Name: Sai.k

Designation: Sales & Senior Business Consultant

Email: info@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com